ArticleJournal of inflammation research2025
Chaihuang Qingfu Pills Protect Against Acute Pancreatitis-Associated Acute Lung Injury Through MMP9-NLRP3-Pyroptosis Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Acute pancreatitis: mechanisms and therapeutic approaches.Signal transduction and targeted therapy · 2026Review
- Demystifying anti-inflammatory therapeutic strategies against pancreatitis and concomitant diseases: a 2025 perspective.Theranostics · 2026Review
- Integration of Network Pharmacology, Transcriptomics, and Metabolomics Strategies to Uncover the Mechanism of Chaihuang Qingfu Pill in Treating Sepsis-Induced Liver Injury.Drug design, development and therapy · 2025Article
- An overview of current research on the modulation of NLRP3 inflammasome by traditional Chinese medicine to combat acute pancreatitis.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe acute pancreatitis associated with acute lung injury (SAP-ALI) is a critical condition with a high mortality rate. Investigating the pathogenesis of SAP-ALI and developing effective treatments are urgently needed. Chaihuang Qingfu Pills (CHQF), a traditional Chinese medicine modified from Qingyi Decoction, has been approved for treating acute pancreatitis (AP). However, its role in SAP-ALI and the underlying mechanisms remain unclear. Methods: 92 AP patients were enrolled to observe the protective effect of CHQF on AP-ALI. L-arginine was used to establish the SAP-ALI animal model. UHPLC-MS/MS was used to identify the components of CHQF absorbed into the serum. Transcriptomics analysis, network pharmacology, and proteomics approaches were used to explore the underlying molecular mechanism. In vivo and in vitro experiments were conducted to validate the relevant findings. Results: Clinical data indicated CHQF reduced the incidence of ALI from 58.33% to 36.36% in AP patients. Animal experiments demonstrated that CHQF decreased mortality, attenuated organ damage, inhibited systemic inflammation and reduced pathological injury in SAP mice. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) identified 146 SAP-related differentially expressed genes (DEGs) from the GSE194331 dataset. UHPLC-MS/MS analysis acquired 26 components absorbed into the blood and 271 associated therapeutic targets. Integrated analysis obtained 52 core targets of CHQF in treating SAP. Proteomic analysis identified 216 proteins associated with CHQF treatment in SAP-ALI. Joint analysis found that MMP9 and NLRP3 were the only common targets. Both in vivo and in vitro experiments confirmed that CHQF reduced the levels of MMP9 and NLRP3 and inhibited pyroptosis in alveolar macrophages (AMs) under SAP conditions. Moreover, the MMP9 inhibitor reduced NLRP3 expression and suppressed AMs pyroptosis. Conclusion: CHQF exerted a protective role in SAP-ALI by inhibiting macrophage pyroptosis through the MMP9-NLRP3 pathway, providing a novel therapeutic strategy for SAP-ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.